Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:CASNumber |
2228196-38-6
|
| gptkbp:clinicalTrialPhase |
Phase 1/2
|
| gptkbp:developedBy |
gptkb:Galecto_Biotech
|
| https://www.w3.org/2000/01/rdf-schema#label |
GB1211
|
| gptkbp:intendedUse |
gptkb:cancer
fibrosis therapy |
| gptkbp:mechanismOfAction |
galectin-3 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational drug
|
| gptkbp:target |
galectin-3
|
| gptkbp:bfsParent |
gptkb:Galecto_Biotech
|
| gptkbp:bfsLayer |
8
|